First Trust Nasdaq Pharmaceuticals ETFFTXH
Type
ETF
Peer group
US equity: Healthcare
Net assets
$29.2M
Expense ratio
0.60%
1-year return
+50.8%
3 years, a year
+17.1%
5 years, a year
+10.6%
12-month yield
1.02%
Holdings
51
What it aims to do.
The First Trust Nasdaq Pharmaceuticals ETF (the Fund ) seeks investment results that correspond generally to the price and yield (before the Funds fees and expenses) of an equity index called the Nasdaq US Smart Pharmaceuticals TM Index (the Index ).
Top 10 holdings.
| Holding | % of fund |
|---|---|
| JNJ Johnson & Johnson | 7.45% |
| BMY Bristol-Myers Squibb Company | 7.36% |
| MRK Merck & Co., Inc | 7.36% |
| ABBV AbbVie Inc. | 7.10% |
| LLY Eli Lilly & Co. | 6.62% |
| PFE Pfizer Inc. | 3.84% |
| REGN Regeneron Pharmaceuticals, Inc. | 3.74% |
| BIIB Biogen Inc | 3.62% |
| GILD Gilead Sciences Inc. | 3.54% |
| CAH Cardinal Health, Inc. | 3.49% |
More on FTXH.
- FTXH overview
- FTXH holdings
- FTXH risk
- FTXH costs
- FTXH money in and out
- FTXH share classes
- Compare FTXH with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.